Skip to main content

Table 2 Tumour-associated antigens and corresponding CAR-Ts, ADCs or BiTEs

From: Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma

Tumour-associated antigens (targets) Biological function Agent Study phase Research tumour type Reference
Alter cancer cell adhesion and motility 5E5 CAR T Mouse Model Leukemia, PDAC, Breast cancer 2016, Immunity
B7-H3 T cell co-stimulatory molecule B7-H3. CAR T Patient derived xenograft PDAC, Ovarian cancer, Neuroblastoma 2019, Cancer Cell
Mesothelin Tumour local invasion and metastasis MSLN CARs Phase I Mesothelioma,
Ovarian carcinoma,
Anetumab ravtansine Phase I Mesothelioma,
Ovarian carcinoma,
PDAC, etc
CEA Tumour surface biomarker CEA-CAR-T Mouse models Colorectal cancer, Gastric cancer, PDAC 2019, Cancer Medicine
Phase II/III PDAC NCT04037241
Mesothelin & CEA   dCAR-T Cell models PDAC 2018, Journal of Hematology and Oncology
Tumour formation and progression CTL targeting KRAS G12D Phase II Metastatic cancers (Colorectal cancer, Glioblastoma, PDAC, Ovarian cancer, Breast cancer) 2016, New England Journal of Medicine
HER2/ERBB2 Tumorigenesis and tumour proliferation Switchable CAR T against HER2 Xenograft model PDAC 2019, Gut
CART-HER2 Phase I Biliary tract cancer, PDAC NCT01935843
DS-8201a Phase I Solid tumors 2016, Clinical Cancer Research
CD133 Tumour stem cells marker CAR T-133 Phase I Hepatocellular carcinoma, Colorectal carcinoma, PDAC NCT02541370
PD-1 Immune checkpoint chPD1 T cells Mouse model Solid tumors (melanoma, renal cancer, liver cancer, PDAC, etc.) 2020, Immunology
MUC16 Tumour surface biomarker DMUC5754A Phase I Ovarian cancer, PDAC NCT01335958
Guanylyl cyclase C Membrane receptor MLN0624 Phase II PDAC NCT02202785
Glypican-1 Cell surface proteoglycan GPC-1-ADC Patient derived xenograft PDAC 2020, British Journal of Cancer
EpCAM Cell adhesion MT110 Phase I Colorectal cancer, Ovarian cancer, Gastric cancer, Lung cancer, Prostate cancer NCT00635596
  1. PDAC pancreatic ductal adenocarcinoma; CAR-T chimeric antigen receptor T cells; ADC antibody-drug conjugate; BiTE bispecific T-cell engager; MSLN Mesothelin; CTL cytotoxic T lymphocytes; PD-1 programmed death-1 receptor